Binh Nguyen

Receiving a warning letter (WL) from the Food and Drug Administration (FDA) can be a critical moment for any company in the pharmaceutical, food, or medical device industries. These letters highlight serious regulatory violations and demand prompt corrective actions. Successfully addressing these concerns is essential not only to avoid legal consequences but also to maintain trust with consumers and regulators. This post explores practical strategies to navigate remediation efforts...

When the FDA completes a Current Good Manufacturing Practice (CGMP) inspection of a drug manufacturing facility whether it's CDER, CBER, and/or CVM products, it often issues a Form 483 to document any observed deviations from regulatory requirements. These observations can range from minor documentation issues to serious manufacturing flaws. How a company responds to these observations can significantly impact its regulatory standing and business operations. This post explores practical...

Drug development has long been a complex, costly, and time-consuming process. Traditional methods often rely heavily on animal testing and lengthy clinical trials, which can delay the arrival of new treatments to patients. Today, new approach methodologies (NAMs) are reshaping how researchers discover and develop medicines. These methods use advanced technologies and alternative testing strategies to improve efficiency, reduce costs, and enhance safety assessments. Previously FDA Announces...